• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Food & Drug Administration (FDA)

Medtronic wins FDA nod for Resolute Onyx drug-eluting stent

May 1, 2017 By Sarah Faulkner

Medtronic's Resolute Onyx

Medtronic (NYSE:MDT) said today that the FDA approved its Resolute Onyx drug-eluting stent. The Fridley, Minn.-based company touted its device as the 1st stent formed by a sinusoidal wave of cobalt alloy wire. The company incorporated a radiopaque inner core within the wire to boost visibility, according to Medtronic. The stent also features thin struts and a polymer […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Stents, Vascular Tagged With: Medtronic

Medtech stories we missed this week: April 28, 2017

April 28, 2017 By Danielle Kirsh

missedmedtechMD

From FDA and Health Canada approvals to joint ventures, here are medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears Joimax Endovapor 2 Joimax announced in an April 26 press release that it has received FDA 510(k) clearance to market its Endovapor 2 Multi-Radio Frequency System. The device generates […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Research & Development Tagged With: Anaconda Biomed, Creganna Medical, Eclipse Aesthetics, Joimax, Mederi Therapeutics, medtech, Millennium Medical Technologies, SiBone, Theraclion

Nordisk wins label update for weight loss drug-device combo

April 27, 2017 By Sarah Faulkner

Novo Nordisk

Novo Nordisk (NYSE:NVO) said today that the FDA approved an updated label for its Saxenda liraglutide weight loss medicine. The therapy’s new label will include data showing that half of patients who received Saxenda and lost at least 5% of their weight after 56 weeks maintained their weight loss for 3 years. The update is based […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Wall Street Beat Tagged With: Novo Nordisk

Alnylam, The Medicines Co., detail Phase III trial for RNA-based heart drug

April 26, 2017 By Sarah Faulkner

anatomical heart

The Medicines Co. (NSDQ:MDCO) and Alnylam Pharmaceuticals (NSDQ:ALNY) said today that they’ve reached a deal with the FDA over a Phase III trial for the companies’ RNA-based cholesterol-lowering drug, inclisiran. If approved, it would be the 1st RNA-interference therapy on the market. The drug is a part of a new group of drugs called PCSK9 […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Food & Drug Administration (FDA), Wall Street Beat Tagged With: Alnylam Pharmaceuticals, Amgen, Regeneron, The Medicines Co.

Sanofi, Regeneron win FDA nod for once-monthly cholesterol injection

April 25, 2017 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) and Regeneron (NSDQ:REGN) said today that the FDA approved the companies’ new supplemental Biologics License Application for a once-monthly, 300 milligram dose of Praluent as a treatment for adults with high low-density lipoprotein cholesterol. The 300 milligram dose is administered using 2 pre-filled pens that each deliver 150 milligrams at an injection site. The […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Regeneron, Sanofi-Aventis

How medtech companies can benefit from agile marketing

April 25, 2017 By Danielle Kirsh

digital marketing on iPad

Getting a medical device to market can be tough. It has to go through several hoops at the FDA, including the 5-step premarket requirements that include: classifying the device; choosing the correct premarket submission; preparing appropriate information for premarket FDA submission; sending a premarket submission to the FDA and communicating with FDA staff during review; and […]

Filed Under: Food & Drug Administration (FDA) Tagged With: agile marketing, incitriomarketing, medical device marketing, medtech

Improving the safety of imported foods through partnerships

April 25, 2017 By Danielle Kirsh

FDA

By: Susan Mayne, Ph.D., Camille Brewer, M.S., R.D., and Donald Prater, D.V.M. At FDA, we recognize that the partnerships we build with other nations are key to our success in giving American consumers confidence in the safety of the foods they choose to serve their families. In passing the FDA Food Safety Modernization Act (FSMA), […]

Filed Under: Food & Drug Administration (FDA) Tagged With: blog, FDA Voice

Medtech stories we missed this week: April 21, 2017

April 21, 2017 By Danielle Kirsh

canyon at sunset

From new and renewed partnerships to FDA approvals, here are medtech stories we missed this week but thought were still worth mentioning. 1. Life Spine receives FDA clearance for cervical spacer system Life Spine announced in an April 19 press release that it has received FDA 510(k) clearance for its Plateau-C Ti Cervical Spacer System. The system uses […]

Filed Under: Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Clearflow, Condor, Getinge, Life Spine, Lifetrack, Mayo Clinic, Owlstone Medical, Physio-Control, Remedent

23andMe is back: FDA allows marketing of genetic health risk tests

April 21, 2017 By Chris Newmarker

23andMe

FDA this month allowed genetic testing company 23andMe to market genetic health risk tests for 10 diseases and conditions including Parkinson’s disease and late-onset Alzheimer’s disease. The de novo premarket review authorization, announced April 6, also included celiac disease, which results in the inability to digest gluten; alpha-1 antitrypsin deficiency, which raises the risk of […]

Filed Under: Business/Financial News, Diagnostics, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: 23andme, FDA, medtech

America’s Got Talent – regulatory science style

April 18, 2017 By Danielle Kirsh

FDA

By: Stephen Ostroff, M.D. Veni Vidi Vici. It translates into English as “I came, I saw, I conquered.” It also happens to be the name chosen by one of the winners of the recently held America’s Got Regulatory Science Talent Competition. FDA recognizes that young scientists are our future. Now in its fifth year, America’s Got Regulatory […]

Filed Under: Food & Drug Administration (FDA) Tagged With: blog, FDA Voice

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 81
  • Page 82
  • Page 83
  • Page 84
  • Page 85
  • Interim pages omitted …
  • Page 95
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS